These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15119921)

  • 1. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
    Alméras N; Després JP; Villeneuve J; Demers MF; Roy MA; Cadrin C; Mottard JP; Bouchard RH
    J Clin Psychiatry; 2004 Apr; 65(4):557-64. PubMed ID: 15119921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
    Karagianis JL; Dunayevich E
    J Clin Psychiatry; 2005 Jan; 66(1):137; author reply 138. PubMed ID: 15669904
    [No Abstract]   [Full Text] [Related]  

  • 3. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
    Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
    Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
    Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
    J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
    Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
    J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
    McKee JR; Bodfish JW; Mahorney SL; Heeth WL; Ball MP
    J Clin Psychiatry; 2005 Sep; 66(9):1161-8. PubMed ID: 16187775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
    Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
    Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
    Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
    Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of novel antipsychotics on glucose and lipid levels.
    Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
    J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.
    Garyfallos G; Dimelis D; Kouniakis P; Sidiropoulos N; Karastergiou A; Lavrentiadis G; Giouzepas J; Fokas K
    Eur Psychiatry; 2003 Oct; 18(6):320-1. PubMed ID: 14611929
    [No Abstract]   [Full Text] [Related]  

  • 18. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
    Meyer JM
    J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
    Misiak B; Frydecka D; Łaczmański Ł; Ślęzak R; Kiejna A
    Eur J Clin Pharmacol; 2014 Dec; 70(12):1433-41. PubMed ID: 25291992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.